Table 1. Clinical and biologic findings... | American Society of Hematology

Table 1.

Clinical and biologic findings of the 5 tyrosine kinase–mutated patients

Patient	Sex	Age	Disease stage at inclusion	Mutation	STI571 dosage (mg/d)	Duration of treatment (mo)	Hematological response	Evolution (mo after onset of treatment)
A	M	57	Chronic phase	Thr315Ile	400	6	No	Died in blastic phase (12 mo)
B	F	54	Accelerated phase	Thr315Ile	600	6	No	Died in blastic phase (12 mo)
C	M	52	Acclerated phase	Thr315Ile	600 during 5 mo	6	No	Alive in accelerated phase (14 mo)
					800 during 1 mo
D	F	45	Accelerated phase	Phe311Ile	600 during 6 mo	Still on therapy	Yes	Alive in accelerated phase (18 mo)
					800 during 12 mo		During 3 mo
E	M	61	Chronic phase	Met351Thr	400 during 12 mo	Still on therapy	Yes	Alive in chronic phase (22 mo)
					600 during 10 mo		During 18 mo

Patient	Sex	Age	Disease stage at inclusion	Mutation	STI571 dosage (mg/d)	Duration of treatment (mo)	Hematological response	Evolution (mo after onset of treatment)
A	M	57	Chronic phase	Thr315Ile	400	6	No	Died in blastic phase (12 mo)
B	F	54	Accelerated phase	Thr315Ile	600	6	No	Died in blastic phase (12 mo)
C	M	52	Acclerated phase	Thr315Ile	600 during 5 mo	6	No	Alive in accelerated phase (14 mo)
					800 during 1 mo
D	F	45	Accelerated phase	Phe311Ile	600 during 6 mo	Still on therapy	Yes	Alive in accelerated phase (18 mo)
					800 during 12 mo		During 3 mo
E	M	61	Chronic phase	Met351Thr	400 during 12 mo	Still on therapy	Yes	Alive in chronic phase (22 mo)
					600 during 10 mo		During 18 mo

mo indicates month.